Research programme: amyloid precursor protein secretase inhibitors - Cotinga Pharmaceuticals
Latest Information Update: 10 Jan 2018
At a glance
- Originator Critical Outcome Technologies
- Developer Cotinga Pharmaceuticals
- Class Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 08 Jan 2018 Critical Outcome Technologies is now called Cotinga Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in Canada (PO)
- 27 Jul 2009 The programme is available for co-development(http://www.criticaloutcome.com/)